Iterum Therapeutics plc
ITRM
$0.99
-$0.007-0.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.69% | -8.01% | -21.95% | 29.63% | 42.56% |
| Total Depreciation and Amortization | 33.72% | 3,162.50% | 0.00% | 14.29% | -98.41% |
| Total Amortization of Deferred Charges | 113.84% | -154.94% | 348.51% | 0.00% | -2.90% |
| Total Other Non-Cash Items | -68.20% | 422.67% | -18.05% | -4.92% | 52.28% |
| Change in Net Operating Assets | 81.27% | -1,845.21% | 97.90% | 55.14% | -238.04% |
| Cash from Operations | 28.10% | -59.28% | 60.47% | 48.34% | -1.87% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -80.70% | 35.75% | -41.77% | -46.68% |
| Cash from Investing | -100.18% | -80.70% | 35.81% | -41.80% | -46.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.19% | 155.56% | 3,151.50% | -97.69% | 1,125.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -160.45% | 155.56% | 3,151.50% | -97.69% | 1,125.30% |
| Foreign Exchange rate Adjustments | -1,050.00% | 92.86% | -55.56% | 33.33% | -92.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -207.03% | 27.15% | 449.36% | -283.08% | 5.02% |